Open-eye warm compress helps with efficacy, compliance

Video

Ken DauSchmidt, founder and CEO of Tear Restore, Inc., shares information about TearResore Mask, the first open-eye warm compress treatment.

Transcript

Ken DauSchmidt: Hello, my name is Ken DauSchmidt. I am the co-founder and CEO of TearRestore. We are here at Vision Expo West talking to thought leaders about everything new dry eye. We have got the first open open-eye warm compress available on the market today. It improves the efficacy of the treatment because the patient's blinking and naturally expressing the meibomian glands throughout. It also improves the compliance of the treatment because they can maintain their activity while they are doing their daily treatment. We have got a clinical study underway and we hope to share those results with you soon.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Ashley Mills, CEO of The Vision Council, gives insight into the decision to move to a single annual meeting and shares the vision for the meeting going forward.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
© 2025 MJH Life Sciences

All rights reserved.